biote Corp.

biote Corp., which completed its de-SPAC merger with Haymaker Acquisition Corp. III (Nasdaq: HYAC), filed a 10-Q with the SEC on May 23, 2022, reflecting its status as a newly public company following the close of that business combination. The SPAC was sponsored by Haymaker Sponsor III, LLC, the vehicle affiliated with the Haymaker team, and conducted its IPO in 2021. biote operates in the healthcare sector, focused on hormone optimization through a network of certified practitioners who administer bioidentical hormone replacement therapy. The 10-Q, filed under accession number 0001193125-22-156540, represents one of the company's earliest periodic disclosures as a combined public entity. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics on biote and hundreds of other SPAC transactions.